comparison of medical treatments in cryptogenic stroke patients with patent foramen ovale: a randomized clinical trial
نویسندگان
چکیده
normal 0 false false false en-us x-none ar-sa background: this randomized clinical trial compared rates of stroke or transient ischemic attack recurrence or death in patients with cryptogenic stroke and patent foramen ovale (pfo) who received medical treatment with aspirin or warfarin. materials and methods: forty-four iranian patients with cryptogenic stroke and patent foramen ovale participated in this randomized, single-blind trial between july 2007 and june 2010. all patients underwent transesophageal echocardiography and contrast-transcranial doppler sonography to confirm the presence of patent foramen ovale. the patients were randomly assigned to receive aspirin or warfarin and were followed for 18 months for the recurrence of ischemic events or death. the principal investigator was blind to the group assignment. this trial is registered under number irct138805192323n1. results: five (11.4%) patients had a stroke, 2 (4.5%) had a transient ischemic attack and 2 (4.5%) died. there was no difference in the rate of ischemic events or death between the aspirin- and warfarin-treated groups (hazard ratio: 0.45; 95% ci: 0.1-1.8; p = 0.259). conclusion: there was no difference in ischemic event recurrence, death rates or side-effects between patients with cryptogenic stroke and patent foramen ovale who were treated with aspirin vs. warfarin.
منابع مشابه
Comparison of medical treatments in cryptogenic stroke patients with patent foramen ovale: A randomized clinical trial
BACKGROUND This randomized clinical trial compared rates of stroke or transient ischemic attack recurrence or death in patients with cryptogenic stroke and patent foramen ovale (PFO) who received medical treatment with aspirin or warfarin. MATERIALS AND METHODS Forty-four Iranian patients with cryptogenic stroke and patent foramen ovale participated in this randomized, single-blind trial betw...
متن کاملEffect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study.
BACKGROUND Patent foramen ovale (PFO) is associated with stroke, but there are no randomized studies to evaluate the efficacy of antithrombotic therapies. METHODS AND RESULTS The PFO in Cryptogenic Stroke Study was a 42-center study that evaluated transesophageal echocardiographic findings in patients randomly assigned to warfarin or aspirin in the Warfarin-Aspirin Recurrent Stroke Study. In ...
متن کاملComparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke.
OBJECTIVES The purpose of this study was to compare the efficacy of medical treatment with percutaneous closure of patent foramen ovale (PFO). BACKGROUND Patients with cryptogenic stroke and PFO are at risk for recurrent cerebrovascular events. METHODS We compared the risk of recurrence in 308 patients with cryptogenic stroke and PFO, who were treated either medically (158 patients) or unde...
متن کاملCryptogenic stroke in patients with patent foramen ovale.
Paradoxical embolism through a patent foramen ovale (PFO) is a commonly identified potential mechanism of ischemic stroke, especially in young patients. The recurrent stroke rate among young cryptogenic stroke patients with a PFO is modest, but higher than normal for their age. Co-existing atrial septal aneurysm is a substantial, and the only definite, potentiator of stroke risk in patients wit...
متن کاملOutcome of patients with cryptogenic stroke and patent foramen ovale.
OBJECTIVES The aim was to estimate the recurrence rate and to define subgroups at increased risk for recurrent cerebral ischaemia in patients with patent foramen ovale (PFO) and so called cryptogenic stroke due to paradoxical embolism. METHODS Patent foramen ovale was diagnosed in 318 patients with otherwise unexplained ischaemic stroke or transient ischaemic attack (TIA). One hundred and fif...
متن کاملPatent Foramen Ovale and Cryptogenic Stroke
To the Editor: The articles by Meier et al.1 and Carroll et al.2 and the corresponding editorial by Messé and Kent3 (March 21 issue) illustrate a major problem in clinical trials. When it is not obvious which of two therapies is better, sufficient numbers of events are essential to reach a conclusion. Performing a prospective, randomized trial is not enough. In the PC Trial (Clinical Trial Comp...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
journal of research in medical sciencesجلد ۱۸، شماره ۲، صفحات ۹۴-۰
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023